Shanghai’s flourishing biopharmaceuticals sector has attracted a major investment from Germany’s Merck KGaA (MRK: DE).
The company has opened a biomanufacturing facility to provide a full range of process development capabilities and services: “Including cell line development, upstream and downstream process development and non-GMP clinical production.”
The move represents a reversal of the traditional role of Western companies in China, where local CMOs have offered global giants a way to reduce costs through outsourcing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze